Valion Bio's CFO and president Lisa Wolf to resign as Entolimod study advances
Wolf will leave her roles as president, COO, and CFO effective December 11, 2026, as Valion awaits early-December results from a government-funded Entolimod efficacy study.
Valion Bio, Inc. disclosed on November 5, 2026 that Lisa Wolf notified the company's Special Committee of her decision to step down from her roles as President, Chief Operating Officer and Chief Financial Officer.1 Her resignation from these positions takes effect December 11, 2026.1 As of the filing date, that resignation had not yet taken effect.1
The leadership change follows an October 30, 2026 announcement that Valion is advancing its lead biologic candidate, Entolimod, into a government-funded efficacy study. The Armed Forces Radiobiology Research Institute will evaluate the therapeutic efficacy of Entolimod after positive safety findings were reported.2 The study phase will test whether treatment given after radiation exposure improves survival in a model of gastrointestinal acute radiation syndrome.2 The study is fully funded by NIAID's Radiation and Nuclear Countermeasures Program under an Interagency Agreement with the Uniformed Services University and AFRRI.2 Top-line results are expected in early December.2
The partial-body irradiation model shields about 2.5% of the animals' bone marrow, letting researchers separate effects from gastrointestinal injury mitigation versus recovery.2 Animals will get one dose of Entolimod or a saline control a day after radiation exposure, then be tracked for 30 days, with survival as the primary endpoint measured against controls.2
The same October filing also disclosed that on October 27, 2026, Valion terminated the employment of General Counsel and Senior Vice President of Legal Affairs Melinda Lackey, effective October 30, 2026.2 Under a Separation Agreement signed October 31, 2026, the company agreed to pay her a $26,750 lump-sum severance, before taxes, within 30 days.2 Valion also agreed to cover her COBRA premiums through November 30, 2026, or until she obtains other employer coverage.2 Lackey forfeited unvested equity and may exercise vested options only per the equity plan's terms.2
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.